| Lasmiditan vs placebo | Rimegepant vs placebo | Ubrogepant vs placebo | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristic | SPARTAN Kuca et al. 2018 [15] | SAMURAI Goadsby et al. 2019 [16] | CENTURION Ashina et al. 2021 [17] | MONONOFU Sakai et al. 2021 [18] | Färkkilä et al. 2012 [19] | Study 301 Lipton et al. 2018 [20] | Study 302 Lipton et al. 2019 [21] | Study 303 Croop et al. 2019 [22] | Marcus et al. 2014 [23] | ACHIEVE I Dodick et al. 2019 [24] | ACHIEVE II Lipton et al. 2019 [25] | Voss et al. 2016 [26] |
Na (baseline) | 1856 | 2583 | 1471 | 691 | 321 | 1162b | 1072 | 1351 | 320 | 1436 | 1465 | 425 |
Female, n (%) | 1552 (83.6) | 2174 (84.2) | 1236 (84) | 574 (83.1) | 277 (86.3) | NA (85.5) | 951 (88.7) | 1147 (84.9) | 277 (86.6) | 1266 (88.2) | 1317 (89.9) | 372 (87.5) |
Meanc age, years (range)d | 41.4–42.4 | 41.8–43.4 | 41.0–42.0 | 44.7–45.7 | 39.5–42.0 | 41.6d | 40.2–40.9 | 40.0–40.3 | 37.9–38.5 | 40.1–40.9 | 41.2–41.7 | 40.5–41.9 |
Meanc duration of disease, years (range)d | 18.9–19.7 | 17.6–19.2 | NA | 23.7–24.7 | NA | NA | NA | NA | NA | 17.9–19.1 | 18.1–19.2 | NA |